‘Bioequivalence’ shown for generic lamotrigine

The EQUIGEN trial shows that switching to and between generic versions of lamotrigine does not affect the plasma levels achieved by patients with epilepsy.

Source: MedWire News - February 17, 2016 Category: Consumer Health News Tags: Epilepsy Source Type: news